ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

3SC009

Its studies are led by 3SBio.

Furthest: phase 1, since Aug 18, 20261 company-led study, 1 open or runningNext primary completion: Mar 30, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
3SBio11 open or runningphase 1since Aug 18, 2026Aug 18, 2026Mar 30, 2028phase 1 · NCT07815002

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 18, 2026First study: phase 1 study in Advanced Solid Tumors PatientsFirst studyNCT07815002 · 100 planned

Ahead

  1. Mar 30, 2028Primary completion: phase 1 study in Advanced Solid Tumors PatientsNCT07815002

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07815002Advanced Solid Tumors Patients1Not yet recruitingMar 30, 2028100

How it is read

Names in the registry

  • “3SC009”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.